Anti-B7-H3 monoclonal antibody (enoblituzumab biosimilar)

Home/ Products / Biosimilar Antibodies

PRODUCT

  • SKU

    DMA1010-100uL

  • Size

    100uL

  • Price

    $320

1
Enoblituzumab (formerly known as MGA271) is a monoclonal antibody against B7-H3 developed by MacroGenics Inc. Enoblituzumab is being evaluated in clinical studies in combination with an anti-PD-1 monoclonal antibody in patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC) and urothelial cancer.
target CD276
gene id 80381
alias B7-H3, CD276, B7 homolog 3
reactivity Human
host Humanized
clonality Monoclonal
clone number MG-A271, MGA271
iso type IgG1
formulation Purified from cell culture supernatant by affinity chromatography; Kept in PBS (pH 7.4) with 0.1% BSA, 0.1% ProClin 300 and 50% Glycerol
applications ELISA, Flow Cytometry
dilution ELISA 1:5000-10000
shipping With ice packs
storage Store at -20°C for at least 1 year. Avoid multiple freeze-thaw cycles.

PRODUCT

  • SKU

    DMA1010-100uL

  • Size

    100uL

  • Price

    $320

1